ClinicalTrials.gg
RecruitingNCT07604324Updated Nov 10, 2026

A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis

A Phase 1 interventional study of DCY636 and Placebo in Dermatitis, Atopic, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Dermatitis, Atopic by Novartis — 2 open to participants now, 3 under way, none of them phase 3. Dermatitis, Atopic · Novartis.

Planned enrollment
19th of 25
63 · median 123
Started
2026
the only one that year
Phase 1
5 of 31
1 open now
Registered
31st of 31
by date

Among the 31 studies in Dermatitis, Atopic by Novartis, this one is the 19th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 1, and was the 31st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 31 studies in Dermatitis, Atopic by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Dermatitis, Atopic by Novartis, or all of them as a file.
02

Study summary

The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.

Read the detailed description

This is a two-part FIH, randomized, placebo-controlled, participant- and investigator-blinded study in healthy participants (Part 1) and participants with moderate to severe AD (Part 2).

03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • Phase 1
  • FIH
  • safety and tolerability
  • healthy volunteers
  • PK
  • atopic dermatitis
  • AD
  • eczema
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Healthy Participants (Part 1)

  • Healthy male and non- female participants 18 to 55 years of age inclusive.

Participants with moderate to severe atopic dermatitis (Part 2)

  • Males and non-pregnant females age 18 years or older
  • Diagnosis of atopic dermatitis for at least 1 year not adequately controlled by topicals
  • Moderate to severe atopic dermatitis as defined by all of the following:

    • EASI score ≥12 at screening visit and ≥16 at baseline (BL) visit
    • IGA score ≥3 at screening visit and baseline visit
    • Total Body surface area (BSA) affected by AD ≥ 10 % at screening visit and baseline visit
    • Peak Pruritus NRS score ≥4 at baseline visit, based on weekly average of daily assessment in the week prior to baseline visit

Key Exclusion Criteria:

All Participants (Part 1, Part 2)

  • Use of other drugs within the last 30 days or 5 half-lives of the other drugs prior to initial dosing, whichever is longer.
  • Meet any of the prohibited medication use criteria at baseline visit.
  • A positive syphilis test result during screening period.
  • Evidence of active or latent TB infection, as determined by T-Spot test during screening period.
  • History of immunodeficiency diseases, or a positive (HIV) test result.
  • Recent (within last half year) or ongoing helminth infection.
  • History of or or serologic evidence for viral hepatitis. A positive Hepatitis B virus surface antigen (HBsAg), Hepatitis B virus core antibody (HBcAb) and/or Hepatitis B surface antibody (HBsAb) test during screening period excludes a participant. A positive test for HBsAb can be included if the test for HBsAg and HBcAb are negative and the history of hepatitis B vaccination is known. Participants with a positive Hepatitis C virus (HCV) antibody test should be excluded.

Healthy Participants (Part 1)

  • Women of childbearing potential
  • Smokers Participants with moderate to severe atopic dermatitis (Part 2)
  • Regular use (more than 2 visits per week) of a tanning booth/parlor or extended sun exposure (per investigator judgement) within 4 weeks prior to baseline visit
  • Have any chronic, uncontrolled medical condition, which would put the participant at increased risk during study participation, such as uncontrolled: diabetes, hypertension, morbid obesity, thyroid, adrenal, cardiovascular, pulmonary, hepatic, renal, neurologic or psychiatric disease, or other disease of concern, as per investigator judgment
  • Women of childbearing potential (WOCBP) are excluded unless they are using highly effective methods of (failure rate \< 1% per year) while taking study treatment and for 202 days (= 5 times the terminal half-life) of study treatment after stopping study treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Part 1- Cohort A1: Dose Level 1 DCY636

    Cohort A1: Dose Level 1 DCY636 in healthy participants.

    Drug: DCY636

  • Experimental
    Part 1- Cohort A2: Dose Level 2 DCY636

    Cohort A2: Dose Level 2 DCY636 in healthy participants.

    Drug: DCY636

  • Experimental
    Part 1- Cohort A3: Dose Level 3 DCY636

    Cohort A3: Dose Level 3 DCY636 in healthy participants.

    Drug: DCY636

  • Experimental
    Part 1- Cohort A4: Dose Level 4 DCY636

    Cohort A4: Dose Level 4 DCY636 in healthy participants.

    Drug: DCY636

  • Experimental
    Part 1- Cohort B1: Dose Level 5 DCY636

    Cohort B1: Dose Level 5 DCY636 in healthy participants.

    Drug: DCY636

  • Experimental
    Part 1- Cohort B2: Dose Level 6 DCY636

    Cohort B2: Dose Level 6 DCY636 in healthy participants.

    Drug: DCY636

  • Experimental
    Part 2- Cohort C1: Dose Level 7 DCY636

    Part 2- Cohort C1: Dose Level 7 DCY636 in participants with moderate to severe atopic dermatitis.

    Drug: DCY636

  • Placebo comparator
    Part 1- Cohort A1: Placebo

    Cohort A1: Placebo in healthy participants.

    Drug: Placebo

  • Placebo comparator
    Part 1- Cohort A2: Placebo

    Cohort A2: Placebo in healthy participants.

    Drug: Placebo

  • Placebo comparator
    Part 1- Cohort A3: Placebo

    Cohort A3: Placebo in healthy participants.

    Drug: Placebo

  • Placebo comparator
    Part 1- Cohort A4: Placebo

    Cohort A4: Placebo in healthy participants.

    Drug: Placebo

  • Placebo comparator
    Part 1- Cohort B1: Placebo

    Cohort B1: Placebo in healthy participants.

    Drug: Placebo

  • Placebo comparator
    Part 1- Cohort B2: Placebo

    Cohort B2: Placebo in healthy participants.

    Drug: Placebo

  • Placebo comparator
    Part 2- Cohort C1: Placebo

    Part 2- Cohort C1: Placebo in participants with moderate to severe atopic dermatitis.

    Drug: Placebo

Interventions

  • DrugDCY636

    Participants will receive DCY636

  • DrugPlacebo

    Participants will receive Placebo

06

What researchers measure

Primary outcomes

  1. Part 1-Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

    Time frame: Up to approximately 202 days

  2. Part 2-Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

    Time frame: Up to approximately 301 days

Secondary outcomes

  1. Part 1-Pharmacokinetic (PK) parameter: Cmax of DCY636

    Cmax is the maximum (peak) observed blood concentration of DCY636 after dose administration.

    Time frame: up to Day 202

  2. Part 1-Pharmacokinetic (PK) parameter: AUC of DCY636

    AUC is the area under the plasma concentration-time curve.

    Time frame: up to Day 202

  3. Part 1-Anti-drug antibodies against DCY636

    To assess immunogenicity (IG) of DCY636.

    Time frame: up to Day 202

  4. Part 2-Pharmacokinetic (PK) parameter: Cmax of DCY636

    Cmax is the maximum (peak) observed blood concentration of DCY636 after dose administration.

    Time frame: up to Day 301

  5. Part 2-Pharmacokinetic (PK) parameter: AUC of DCY636

    AUC is the area under the plasma concentration-time curve.

    Time frame: up to Day 301

  6. Part 2-Anti-drug antibodies against DCY636

    To assess immunogenicity (IG) of DCY636.

    Time frame: up to Day 301

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative Site
    Fukuoka, 8120025, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 19 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 22, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Jan 27, 2028
CompletionEst.
Jan 28, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07604324
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jun 2, 2026
Primary completion
Jan 27, 2028 (estimated)
Completion
Jan 28, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+81337978748
Novartis Pharmaceuticals
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion